Ποια είναι η τιμή για Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

Η τιμή για Wuhan Hiteck Biological Pharma Co.,Ltd (300683) είναι $3.71

Ποια είναι η κεφαλαιοποίηση αγοράς για Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

Η κεφαλαιοποίηση αγοράς για Wuhan Hiteck Biological Pharma Co.,Ltd (300683) είναι $486.16M

Wuhan Hiteck Biological Pharma Co.,Ltd (300683) Τιμή και Κεφαλαιοποίηση Αγοράς

Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.

Η τιμή για 300683	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$40,683.40 $486.16M	NVDA	$5.325T	+1,095,264.49%
$35,211.89 $486.16M	AAPL	$4.609T	+947,948.95%
$31,029.81 $486.16M	GOOG	$4.062T	+835,350.10%
$29,007.97 $486.16M	MSFT	$3.797T	+780,913.89%
$21,466.63 $486.16M	AMZN	$2.810T	+577,870.08%

Η τιμή για 300683

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$40,683.40 $486.16M